Alnylam Pharmaceuticals
ALNY
#680
Rank
NZ$62.49 B
Marketcap
NZ$468.05
Share price
2.33%
Change (1 day)
-13.07%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): NZ$1.50 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$4.28 Billion. In 2025 the company made an earning of NZ$1.08 Billion, an increase over its 2024 earnings that were of -NZ$0.41 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) NZ$1.50 B38.57%
2025 NZ$1.08 B-369.48%
2024 -NZ$0.41 Billion-24.59%
2023 -NZ$0.54 Billion-67.84%
2022 -NZ$1.67 Billion36.93%
2021 -NZ$1.22 Billion-8.04%
2020 -NZ$1.32 Billion-15.66%
2019 -NZ$1.57 Billion12.23%
2018 -NZ$1.4 Billion62.91%
2017 -NZ$0.86 Billion17.78%
2016 -NZ$0.73 Billion43.44%
2015 -NZ$0.51 Billion60.69%
2014 -NZ$0.32 Billion98.2%
2013 -NZ$0.16 Billion
2011 -NZ$93.75 Million27.48%
2010 -NZ$73.54 Million-10.92%
2009 -NZ$82.55 Million95.77%
2008 -NZ$42.17 Million
2006 -NZ$67.56 Million-9.13%
2005 -NZ$74.35 Million34.74%
2004 -NZ$55.18 Million36.79%
2003 -NZ$40.34 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
NZ$26.99 B 1,714.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$13.09 B 780.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$8.81 B 492.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-NZ$1.21 Billion-180.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-NZ$81.11 Million-105.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-NZ$0.28 Billion-118.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$3.88 B 161.13%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.59 B-60.31%๐Ÿ‡บ๐Ÿ‡ธ USA